Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INSMBullishIndustry Newsnews

High materiality8/10

Insmed Reports Positive 12-Month TPIP OLE PAH Data Supporting PALM-PAH

Jul 16, 2026, 7:03 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The data de-risks the TPIP program, reinforces clinical benefit signals, and supports a near-term Phase 3 pathway, which can lift valuation and attract investor attention ahead of PALM-PAH milestones.

AI summary

What happened, with direct paths to the underlying reporting

Insmed announced positive 12-month data from TPIP’s open-label extension in PAH, showing sustained improvements in 6MWD, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 risk scores, with placebo-crossed patients achieving similar outcomes. Safety remained acceptable up to 1,280 µg daily; PALM-PAH Phase 3 is underway, potentially accelerating TPIP’s approval pathway.

12-month OLE TPIP data shows sustained 6MWD and NT-proBNP gains.
Placebo Crossed group matched TPIP outcomes at Month 12.
Doses up to 1,280 µg daily tolerated.
PALM-PAH Phase 3 underway; investor call July 16, 2026.
TPIP may become PAH prostanoid of choice.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.